Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 14

1.

(Z)-5-(3,4,5-Tri-meth-oxy-styr-yl)-2,3-di-hydro-thieno[3,4-b][1,4]dioxine.

Liu YT, Chu G.

Acta Crystallogr Sect E Struct Rep Online. 2014 Mar 5;70(Pt 4):o384. doi: 10.1107/S1600536814004437.

2.
3.

A perspective on vascular disrupting agents that interact with tubulin: preclinical tumor imaging and biological assessment.

Mason RP, Zhao D, Liu L, Trawick ML, Pinney KG.

Integr Biol (Camb). 2011 Apr;3(4):375-87. doi: 10.1039/c0ib00135j.

4.

Anti-angiogenesis therapies: their potential in cancer management.

Eichholz A, Merchant S, Gaya AM.

Onco Targets Ther. 2010 Jun 24;3:69-82.

5.

Antibody drug-conjugates targeting the tumor vasculature: Current and future developments.

Gerber HP, Senter PD, Grewal IS.

MAbs. 2009 May-Jun;1(3):247-53. Review.

6.

Design and synthesis of novel pinacolylboronate containing combretastatin 'antimitotic agent' analogues.

Das BC, Mahalingam SM, Evans T.

Tetrahedron Lett. 2009 Jun 24;50(25):3031-3034.

7.

Liposomal encapsulation enhances the antitumour efficacy of the vascular disrupting agent ZD6126 in murine B16.F10 melanoma.

Fens MH, Hill KJ, Issa J, Ashton SE, Westwood FR, Blakey DC, Storm G, Ryan AJ, Schiffelers RM.

Br J Cancer. 2008 Oct 21;99(8):1256-64. doi: 10.1038/sj.bjc.6604675.

8.

Challenges of antiangiogenic cancer therapy: trials and errors, and renewed hope.

Medina MA, Muñoz-Chápuli R, Quesada AR.

J Cell Mol Med. 2007 May-Jun;11(3):374-82. Review.

9.

Highly potent triazole-based tubulin polymerization inhibitors.

Zhang Q, Peng Y, Wang XI, Keenan SM, Arora S, Welsh WJ.

J Med Chem. 2007 Feb 22;50(4):749-54.

10.

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126.

Bozec A, Lassalle S, Gugenheim J, Fischel JL, Formento P, Hofman P, Milano G.

Br J Cancer. 2006 Sep 18;95(6):722-8.

11.

Diffusion-weighted magnetic resonance imaging allows noninvasive in vivo monitoring of the effects of combretastatin a-4 phosphate after repeated administration.

Thoeny HC, De Keyzer F, Chen F, Vandecaveye V, Verbeken EK, Ahmed B, Sun X, Ni Y, Bosmans H, Hermans R, van Oosterom A, Marchal G, Landuyt W.

Neoplasia. 2005 Aug;7(8):779-87.

12.
13.

Angiogenesis: a curse or cure?

Gupta K, Zhang J.

Postgrad Med J. 2005 Apr;81(954):236-42. Review.

14.

ZD6126 inhibits orthotopic growth and peritoneal carcinomatosis in a mouse model of human gastric cancer.

McCarty MF, Takeda A, Stoeltzing O, Liu W, Fan F, Reinmuth N, Akagi M, Bucana C, Mansfield PF, Ryan A, Ellis LM.

Br J Cancer. 2004 Feb 9;90(3):705-11.

Items per page

Supplemental Content

Support Center